204 related articles for article (PubMed ID: 25337199)
41. Serum proteomic features for detection of endometrial cancer.
Zhu LR; Zhang WY; Yu L; Zheng YH; Zhang JZ; Liao QP
Int J Gynecol Cancer; 2006; 16(3):1374-8. PubMed ID: 16803533
[TBL] [Abstract][Full Text] [Related]
42. SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma.
Huang YJ; Xuan C; Zhang BB; Liao M; Deng KF; He M; Zhao JM
J Exp Clin Cancer Res; 2009 Jun; 28(1):85. PubMed ID: 19534814
[TBL] [Abstract][Full Text] [Related]
43. [Screen of phosphopeptide specific for acute leukemia].
Peng HL; Dai CW; Zhang GS; Gu TL; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):163-8. PubMed ID: 22781597
[TBL] [Abstract][Full Text] [Related]
44. Identification of signature genes by microarray for acute myeloid leukemia without maturation and acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RARalpha).
Morikawa J; Li H; Kim S; Nishi K; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W; Kobayashi T
Int J Oncol; 2003 Sep; 23(3):617-25. PubMed ID: 12888896
[TBL] [Abstract][Full Text] [Related]
45. Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies.
Bruserud Ø; Selheim F; Hernandez-Valladares M; Reikvam H
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928061
[TBL] [Abstract][Full Text] [Related]
46. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.
Forthun RB; Aasebø E; Rasinger JD; Bedringaas SL; Berven F; Selheim F; Bruserud Ø; Gjertsen BT
J Proteomics; 2018 Feb; 173():32-41. PubMed ID: 29175091
[TBL] [Abstract][Full Text] [Related]
47. Plasma proteomic pattern as biomarkers for ovarian cancer.
Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
[TBL] [Abstract][Full Text] [Related]
48. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
49. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
50. Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia.
Çelik H; Lindblad KE; Popescu B; Gui G; Goswami M; Valdez J; DeStefano C; Lai C; Thompson J; Ghannam JY; Fantoni G; Biancotto A; Candia J; Cheung F; Sukumar G; Dalgard CL; Smith RH; Larochelle A; Dillon LW; Hourigan CS
Blood Adv; 2020 Jan; 4(2):367-379. PubMed ID: 31985806
[TBL] [Abstract][Full Text] [Related]
51. Image morphometry of acute leukemias. Comparison between lymphoid and myeloid subtypes.
Rajesh L; Pattari SK; Garewal G; Dey P; Srinivasan R
Anal Quant Cytol Histol; 2004 Feb; 26(1):57-60. PubMed ID: 15032082
[TBL] [Abstract][Full Text] [Related]
52. Proteomic Protocol in Esophageal Adenocarcinoma.
Kelly P
Methods Mol Biol; 2018; 1756():281-293. PubMed ID: 29600378
[TBL] [Abstract][Full Text] [Related]
53. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.
Braoudaki M; Tzortzatou-Stathopoulou F; Anagnostopoulos AK; Papathanassiou C; Vougas K; Karamolegou K; Tsangaris GT
Amino Acids; 2011 Mar; 40(3):943-51. PubMed ID: 20711619
[TBL] [Abstract][Full Text] [Related]
54. Distribution of the cytoskeletal protein, Nestin, in acute leukemia.
Du X; Yang XH; Wu YF; Liang J; Zhang J; Huang ZC; Zhu ZP; Lin W; Zou MX; Wen JY; Wu SJ; Guo R; Zhang XM; Lahn BT; He F; Xiang AP
Biotech Histochem; 2015 Jul; 90(5):384-94. PubMed ID: 25839093
[TBL] [Abstract][Full Text] [Related]
55. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
[TBL] [Abstract][Full Text] [Related]
56. Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets.
López-Pedrera C; Villalba JM; Siendones E; Barbarroja N; Gómez-Díaz C; Rodríguez-Ariza A; Buendía P; Torres A; Velasco F
Proteomics; 2006 Apr; 6 Suppl 1():S293-9. PubMed ID: 16521150
[TBL] [Abstract][Full Text] [Related]
57. Endocan, a potential prognostic and diagnostic biomarker of acute leukemia.
Xu Z; Zhang S; Zhou Q; Wang Y; Xia R
Mol Cell Biochem; 2014 Oct; 395(1-2):117-23. PubMed ID: 24934240
[TBL] [Abstract][Full Text] [Related]
58. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).
Hong H; Dragan Y; Epstein J; Teitel C; Chen B; Xie Q; Fang H; Shi L; Perkins R; Tong W
BMC Bioinformatics; 2005 Jul; 6 Suppl 2(Suppl 2):S5. PubMed ID: 16026602
[TBL] [Abstract][Full Text] [Related]
59. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
Kornblau SM; Singh N; Qiu Y; Chen W; Zhang N; Coombes KR
Clin Cancer Res; 2010 Mar; 16(6):1865-74. PubMed ID: 20215543
[TBL] [Abstract][Full Text] [Related]
60. [Proteomics analysis of bone marrow cells of acute myeloid leukemia M2a and prognostic significance thereof].
Tian S; Meng FY; Tang JM
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(8):538-41. PubMed ID: 17459203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
